The United States government has committed to support Tanzania's efforts in the fight against COVID-19 pandemic by strengthening management of the pandemic cases in referral hospitals. The support channeled through the US Agency for International Development (USAID) will be implemented through a project that was launched yesterday in Dodoma Capital.
The 10-month project worth over 1.7bn/- aims to ensure health facilities provide the best care for COVID-19 patients with critical needs, ultimately improving their chances of survival and recovery speed. Execution of the project will be carried out at the Dodoma Regional Referral Hospital (Dodoma), Bombo Regional Referral Hospital (Tanga), Mount Meru Regional Referral Hospital (Arusha) and Sekou Toure Regional Referral Hospital (Mwanza).
Speaking at the launch of the project, the USAID Project Management Specialist, Dr. Miriam Kombe, said the project will also strengthen health care workers' management of the cases to enable an effective, life-saving and sustainable COVID-19 response. "This support includes mitigating the impact of the pandemic on society, equitable access and delivery of COVID-19 vaccinations, reducing morbidity and mortality from COVID-19 and preventing and mitigating the impacts of COVID-19 on our AIDS relief programmes and beneficiaries." Dr. Kombe added
"The COVID-19 pandemic is among the most pressing challenges to the health, well-being and economic security of all people. We must work together to address this pandemic with urgency." According to a statement issued by the US Embassy in Tanzania, the project is going to be implemented by Save the Children, noting that the funds will be used to support the provision of oxygen therapy equipment and training for health care workers. Such training will focus on the appropriate use and maintenance of the equipment, in order to provide quality services and expand critical care for COVID-19 patients with respiratory distress.
The statement stated that training will also include the development and distribution of job aids, based on approved national guidelines, as well as follow-up support for oxygen therapy after the departure of trainers. "The COVID-19 pandemic is a global emergency with unprecedented reach and rapidly evolving health system challenges," noted the statement. In the statement the US government expressed commitment to work side by side with the Government of Tanzania on their National COVID-19 Response Plan.
Such commitment includes partnering with all stakeholders in Tanzania's Health sector to mitigate effects of the pandemic and ensure the health and safety of the entire community. "USAID's broad support includes mitigating the impact of the pandemic on society, equitable access and delivery of COVID-19 vaccinations, reducing morbidity and mortality from COVID-19, and preventing and mitigating the impacts of COVID-19 on HIV / AIDS relief programmes and beneficiaries. To date, USAID has invested a total of $25,1m in these areas," noted the statement.
On July 24th, this year Tanzania received the first batch of 1,058,400 doses of the Johnson&Johnson vaccine donated by the US government through the COVAX arrangement. In mounting efforts to contain the spread of COVID-19, the government over the past two months rolled out its countrywide vaccination campaign, whereas over 350,000 people have already taken the COVID-19 jabs.
Distributed by APO Group on behalf of Embassy of the United Republic of Tanzania Tel Aviv, Israel.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
